NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Cryoport, Inc. CYRX
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$176.2M
▲ 12.4% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
17.3%
Net margin · FY25
44.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 176.2M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
44 cents of every revenue dollar became profit this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
17.3%
Return on equity, FY2025
ROE
Operating margin-20.9%
Net margin44.4%
Return on assets10.7%
Each USD of equity produced 17 cents of profit this year.
Returned to shareholders
USD 6.0M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 6.0M
Share of profit7.7%
Consecutive raises—
USD 6.0M in buybacks — 8% of the year's profit went back to shareholders.
Growth
+17.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−9.4%
+17.5%
+40.5%
+48.3%
Returned to shareholders
−45.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years+25.1%
Change, 10 years+306.9%
The share count grew 25% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 765.0M
total assets, end of FY2025
Total assetsUSD 765.0M
EquityUSD 502.6M
CashUSD 250.5M
Current ratio2.17×
Equity funds 66% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.2
0.2
0.2
0.2
0.2
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.1
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.1
−0.1
−0.1
−0.0
−0.3
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
17.3
−25.8
−19.1
−6.2
−53.8
−12.8
−22.2
−33.9
−67.0
−298.8
−733.0
·
·
−766.1
−161.9
−103.4
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
64 of 64
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed